BMS 986142

Drug Profile

BMS 986142

Alternative Names: BMS-986142

Latest Information Update: 04 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Sjogren's syndrome in Puerto Rico (PO) (NCT02843659) after October 2016
  • 01 Oct 2016 Phase-II clinical trials in Sjogren's syndrome in USA (PO) (NCT02843659)
  • 01 Sep 2016 Bristol-Myers Squibb completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02880670)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top